Bafilomycin A1 is a highly potent, selective inhibitor of vacuolar H+-ATPases (IC50 = 0.6 - 1.5 nM in bovine chromaffin granules). Selective for v-ATPase over other ATP hydrolyzing enzymes such as F-ATPases and the H+/K+-ATPase (P-ATPase). Thought to inhibit autophagy either by blocking autophagosome-lysosome fusion (in H4IIE cells), or by blocking lysosomal degradation. Bafilomycin A1 accelerates wound healing in db/db mice. Low dose Bafilomycin A1 attenuates patient-derived CD34+CD19+ leukemia stem cells (LSC) and inhibits LSC proliferation in an animal model. Bafilomycin A1 impairs Zika virus infection
in vitro
.
Caractéristiques techniques
| Marque | Tocris Bioscience |
|---|
| Réf. B-LABO | BL-RE-165680 |
|---|
| Réf. fabricant | 30000853 |
|---|
| Nom chimique ou matériau | (3Z,5E,7R,8S,9S,11E,13E,15S,16R)-8-Hydroxy-16-[(1S,2R,3S)-2-hydroxy-1-methyl-3-[(2R,4R,5S,6R)-tetrahydro-2,4-dihydroxy-5-methyl-6-(1-methylethyl)-2H-pyran-2-yl]butyl]-3,15-dimethoxy-5,7,9,11-tetramethyloxacyclohexadeca-3,5,11,13-tetraen-2-one |
|---|
| CAS | 88899-55-2 |
|---|
| Quantité | 100 μg |
|---|
| Cible | H+-ATPase Inhibitors |
|---|
| Formule moléculaire | C<sub>35</sub>H<sub>58</sub>O<sub>9</sub> |
|---|
| Pureté | 0.95 |
|---|
Une question, une configuration particulière ?
Contactez-nous pour un devis.
